Prelude Capital Management, LLC Vertex Pharmaceuticals Inc Transaction History

Prelude Capital Management, LLC

$1.57 Billion
Q3 2024

A detailed history of Prelude Capital Management, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Prelude Capital Management, LLC holds 5,905 shares of VRTX stock, worth $2.41 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares

5,905

Previous 5,905 -0.0%

Holding current value

$2.41 Million

Previous $2.75 Million -0.0%

% of portfolio

0.17%

Previous 0.11%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$460.0 - $505.78 $13,340 - $14,667	29 Added 0.49%	5,905 $2.75 Million
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $40,852 - $50,495	104 Added 1.8%	5,876 $2.75 Million
Q1 2024 May 15, 2024	SELL	$407.69 - $446.08 $440,712 - $482,212	-1,081 Reduced 15.77%	5,772 $2.41 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $299,096 - $358,112	872 Added 14.58%	6,853 $2.79 Million
Q3 2023 Nov 14, 2023	SELL	$338.18 - $362.46 $195,129 - $209,139	-577 Reduced 8.8%	5,981 $2.08 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $1.8 Million - $2.01 Million	5,713 Added 676.09%	6,558 $2.31 Million
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $138,499 - $157,995	-489 Reduced 36.66%	845 $266,000
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $381,203 - $428,854	1,334 New	1,334 $385,000
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $1.55 Million - $1.93 Million	-6,587 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $716,736 - $844,759	3,237 Added 96.63%	6,587 $1.72 Million
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $194,002 - $244,901	1,096 Added 48.62%	3,350 $736,000
Q3 2021 Nov 15, 2021	SELL	$181.39 - $202.99 $172,320 - $192,840	-950 Reduced 29.65%	2,254 $409,000
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $312,839 - $388,070	-1,566 Reduced 32.83%	3,204 $762,000
Q4 2019 Feb 14, 2020	SELL	$166.71 - $223.91 $512,799 - $688,747	-3,076 Reduced 39.2%	4,770 $1.04 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $1.09 Million - $1.22 Million	6,533 Added 497.56%	7,846 $1.33 Million
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $494,982 - $572,442	-3,007 Reduced 69.61%	1,313 $241,000
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $608,093 - $723,115	3,714 Added 612.87%	4,320 $795,000
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $1.44 Million - $1.82 Million	-9,464 Reduced 93.98%	606 $100,000
Q3 2018 Nov 14, 2018	SELL	$167.73 - $192.74 $3.67 Million - $4.21 Million	-21,858 Reduced 68.46%	10,070 $1.94 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $1.99 Million - $2.32 Million	13,662 Added 74.79%	31,928 $5.43 Million
Q1 2018 May 15, 2018	SELL	$151.6 - $177.13 $833,648 - $974,037	-5,499 Reduced 23.14%	18,266 $2.98 Million
Q4 2017 Feb 14, 2018	BUY	$137.28 - $155.55 $550,492 - $623,755	4,010 Added 20.3%	23,765 $3.56 Million
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $2.93 Million - $3.21 Million	19,755	19,755 $3 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.

Account

Prelude Capital Management, LLC Vertex Pharmaceuticals Inc Transaction History